Pfizer’s Paxlovid Reduces COVID-19 Risk in Seniors Regardless of Vaccine Status, Study Finds
A new study in Israel conducted during the rise of the Omicron variant found that Pfizer Inc.’s antiviral treatment Paxlovid reduced COVID-19 hospitalization and death rates in vaccinated and unvaccinated patients 65 years and older. Great!
Photo Credit: Brett Jordan